SCHEMBL3082771

SCHEMBL3082771

NC(=O)c1ccn2ncc(C=O)c2c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.45
ERN1 O75460 6/20 0.38
TGFBR1 P36897 1/20 0.37
FLT3 P36888 1/20 0.36
KDM4E B2RXH2 1/20 0.36
BRD4 O60885 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BRPF1 P55201 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
DRD2 P14416 5/20 0.36
DRD1 P21728 5/20 0.36
DRD4 P21917 5/20 0.36
HTR2A P28223 5/20 0.36
DRD3 P35462 5/20 0.36
JAK1 P23458 4/20 0.35
JAK3 P52333 4/20 0.35
JAK2 O60674 3/20 0.35
TYK2 P29597 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3082758 0.86 UNG (0.38) PIK3CAERN1KDM4EALDH1A1DRD2
SCHEMBL3082772 0.81 PIK3CD (0.48) PIK3CAERN1ALDH1A1DRD2DRD1
SCHEMBL3076808 0.78 DRD2 (0.36) PIK3CADRD2DRD1DRD4HTR2A
SCHEMBL3065072 0.78 HTR2A (0.39) PIK3CAERN1DRD2DRD1DRD4
SCHEMBL30478898 0.75 JAK2 (0.42) PIK3CAJAK1JAK3JAK2TYK2
SCHEMBL3075903 0.74 EPHB3 (0.44) PIK3CAERN1ALDH1A1SMN1; SMN2DRD2
SCHEMBL31595984 0.74 PIK3CA (0.38) PIK3CAFLT3KDM4EALDH1A1SMN1; SMN2
SCHEMBL3064017 0.74 PIK3CA (0.44) PIK3CAERN1DRD2DRD1DRD4
SCHEMBL3073487 0.74 PIK3CA (0.43) PIK3CAALDH1A1DRD2DRD1DRD4
SCHEMBL3084225 0.74 PTGS2 (0.38) KDM4EALDH1A1HSD17B10DRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP claimed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO claimed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY TP53, PNPO, DPYD PIK3CA 410/4885ERN1 1863/4885TGFBR1 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.